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Myosin-binding protein C (MyBP-C) is a ~130 kDa protein of the thick fila-
ments of vertebrate skeletal and cardiac muscle. It consists of a linear array
of ten or eleven globular, 10-kDa domains from the immunoglobulin (Ig)
and fibronectin type III families, and an additional, MyBP-C-specific motif.
The cardiac isoform, cMyBP-C, plays a key role in modulating cardiac func-
tion, and mutations in MyBP-C cause heart disease. Despite its discovery 40
years ago, the mechanism of MyBP-C function remains poorly understood.
In vitro studies suggest that it could modulate contraction by binding to thin fil-
aments, but there has been no evidence for this in situ. We used electron tomog-
raphy of exceptionally well-preserved skeletal muscle to study the 3D
organization of MyBP-C in the intact sarcomere. The tomogram shows that
MyBP-C projects perpendicular to the thick filament surface and reaches neigh-
boring thin filaments. This thick-thin filament bridge suggests a possible phys-
ical basis for modulating filament sliding and thus contraction. In vitro, binding
to actin has been shown to occur via MyBP-C’s N-terminal end. To understand
the structural basis of this binding, we used negative stain electron microscopy
and 3D reconstruction to study F-actin decorated with bacterially expressed
N-terminal cMyBP-C fragments. Clear decoration was obtained under a variety
of salt conditions. 3D reconstructions showed MyBP-C density starting over
subdomain 1 of actin and extending tangentially towards actin’s pointed end.
Molecular fitting with an atomic structure of a MyBP-C Ig domain suggested
that most of the N-terminal domains may be well ordered on actin. The location
of binding was such that it appeared to overlap the relaxed (low Ca2þ) position
of tropomyosin but not the activated position. This suggests that MyBP-C
might help determine the state of thin filament activity by modulating tropomy-
osin position on actin.
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Cardiac myosin binding protein-C (cMyBP-C) is a thick filament associated
protein that performs both regulatory and structural roles within cardiac sarco-
meres. It is a member of the immunoglobulin (Ig) superfamily of proteins con-
sisting of 8 Ig- and 3 fibronectin (FNIII)-like subdomains along with a unique
regulatory sequence referred to as the M-domain whose structure is unknown.
Here we used atomic force microscopy (AFM) to probe the structure and me-
chanical properties of the different subdomains of native and recombinantly ex-
pressed cMyBP-C molecules. Results demonstrate that cMyBP-C exhibits
complex mechanical behavior under load and contains multiple domains
with distinct mechanical properties. The Ig and FNIII-like domains unfold
over a range of relatively low forces (50-190 pN), whereas the M-domain is
readily extensible at forces <50 pN and is likely to be an intrinsically disor-
dered segment of cMyBP-C. Additional extensible segments of cMyBP-C
are likely to include linkers between the Ig domains such as the proline-
alanine rich sequence between domains C0 and C1. Taken together these re-
sults suggest that cMyBP-C is compliant and readily extensible, potentially
conferring structural and functional plasticity to cMyBP-C during the course
of a single heart beat. Supported by NIH HL080367.
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Cardiac myosin binding protein-C (cMyBP-C) is a sarcomeric thick filament
assembly protein with regulatory functions in the heart. The cMyBP-C protein
differs from the skeletal isoform in that it has a small insertion near the car-
boxyl terminus that contains 3 phosphorylatable serines, Ser-273, 282 and
302. While the precise functional correlates of cMyBP-C phosphorylation re-
main obscure, we do know that cMyBP-C is targeted by multiple kinases, such
as PKA, PKC, RSK, PKD, CaMKII and PKG, suggesting that it plays a vital
role in cardiac signaling. We previously reported that cMyBP-C phosphoryla-
tion is essential for normal heart function and that Ser-282 phosphorylation iscritical for the subsequent phosphorylation of Ser-302 and normal cardiac
function. However, the role of Ser-282 cMyBP-C phosphorylation in cardiac
function, particularly as it affects contractile properties and sarcomere organi-
zation, is unclear. Therefore, to better understand the mechanisms and signif-
icance of cMyBP-C phosphorylation, we established several transgenic mouse
models to determine the necessity and sufficiency of Ser-282 phosphorylation
for normal cardiac function. Our findings suggested that cMyBP-C phosphor-
ylation at Ser-282 is essential for normal cardiac function and that dephosphor-
ylation at this site accelerates cMyBP-C degradation and cleavage of a 40 kDa
fragment. During MI, we showed that cMyBP-C is extensively fragmented
when dephosphorylated and that such fragmentation correlates well with con-
tractile dysfunction and heart failure. Meanwhile, we also established that the
release of cMyBP-C in the blood post-MI could be a potential diagnostic bio-
marker for MI. Overall, these studies show that Ser-282 phosphorylation is
a critical determinant of Ser-302 phosphorylation and that cMyBP-C dephos-
phorylation accelerates its degradation and release into the circulation. In con-
clusion, we provide strong evidence that cMyBP-C phosphorylation directly
affects the heart’s contractile properties, sarcomere organization and
cardioprotection.
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During recent years it has become increasingly evident that cardiac myosin
binding protein C (cMyBP-C) exerts an important role in regulation of
sarcomere function with consequences for in vivo cardiac performance.
The functional role of cMyBP-C is tightly regulated by kinase-mediated
phosphorylation. The most important kinase which phosphorylates
cMyBP-C in vivo is protein kinase A (PKA), which is activated upon stimu-
lation of the b-adrenergic receptors during exercise. In end-stage failing hu-
man myocardium, reduced phosphorylation of cMyBP-C has been reported
using 1-dimensional and 2-dimensional gel electrophoresis. This reduced
phosphorylation has been attributed to down-regulation and desensitization
of the b-adrenergic receptor pathway in end-stage human heart failure.
Low levels of cMyBP-C phosphorylation were also found in patients with
familial hypertrophic cardiomyopathy (FHC), which is frequently caused by
mutations in genes encoding sarcomeric proteins, with one exception: in
FHC patients with mutations in the gene which encodes cMyBP-C
(MYBPC3), phosphorylation of cMyBP-C was unaltered compared to non-
failing donor hearts. cMyBP-C can be phosphorylated in vivo on at least three
serine sites (Ser273, Ser282 and Ser 302), all of which are located in the car-
diac isoform specific M region. At least one other site should exist in humans.
With tandem mass spectrometry we recently identified a fourth phosphoryla-
tion site on Ser133, which is present in the Pro-Ala rich region that links the
C0 and C1 domains. Preliminary data indicate that Ser133 is not phosphory-
lated by PKA. Analysis of phosphorylation on Ser133 in failing and donor
samples revealed lower levels of Ser133 phosphorylation in several forms
of cardiac disease compared to non-failing myocardium. Overall, our studies
indicate that diverse cMyBP-C phosphorylation patterns exist in human car-
diomyopathies, which may in part underlie sarcomere dysfunction observed
in human heart failure.Symposium: Materials Science Meets Biology
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Our laboratory is interested in engineering tools and systems using nanoparticle
scaffolds to transform the diagnosis and treatment of cancer. We aim to inte-
grate nanomaterials with enhanced nanoscale properties and bioresponsive
functionalities with our knowledge of the tumor microenvironment to explore
this paradigm. Towards this end, we have developed and investigated nanopar-
ticle conjugates based on three nanoparticle cores that harness features of the
nanoscale: semiconductor quantum dots that exhibit size-based optical proper-
ties, dextran-coated iron oxide particles whose assembly alters the spin-spin re-
laxation time of hydrogen protons on magnetic resonance imaging, and
polymer-coated gold nanorods that interact resonantly with near-infrared light.
Our studies have shown how these nanoparticles specifically designed to
